MASH peptides on the horizon · why Panya isn't routing yet (May 2026)

MASH (metabolic-dysfunction-associated steatohepatitis, formerly NASH) is the indication where the GLP-1 + glucagon dual agonists could land their first regulatory approvals separate from weight management. As of May 2026, exactly one drug is FDA-approved for MASH: resmetirom (Rezdiffra, Madrigal). Three injectable peptides are racing for the second slot · survodutide and pemvidutide on the GLP-1 + glucagon mechanism, with retatrutide's triple-agonist program a longer-tail option.

This is where the science is. This is what we are watching. This is also a piece where we explicitly do not route yet · and an explanation of why a "watching" framing serves readers better than a confident routing call we cannot defend.

What's actually approved today

Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) received FDA accelerated approval in March 2024 for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). It is a thyroid hormone receptor beta-selective agonist · not a peptide, not a GLP-1, mechanistically distinct from everything else in this post. Daily oral, no cold chain, no injection.

Phase 3 (MAESTRO-NASH) endpoints at 52 weeks: 25.9% achieved MASH resolution at the 80mg dose, 29.9% at 100mg, against 9.7% on placebo. Fibrosis improvement at 24.2% (80mg), 25.9% (100mg) vs 14.2% placebo. Modest LDL reduction. Safety profile clean in the trial cohort.

Commercial trajectory matters more than trial data for routing. Madrigal launched in mid-2024. Q1 2025 net revenue was reported at ~$103M; Q4 2025 at ~$240M; full-year 2025 at ~$770M. Insurance coverage gradual but expanding · Express Scripts + CVS Caremark adding it to formularies through 2025-2026. Cash list price at launch was ~$47k/year · prior-auth burden real but not insurmountable for properly-staged patients with documented F2-F3 fibrosis on biopsy or non-invasive equivalent.

This is the comparator any MASH peptide approval has to beat or complement. Resmetirom is the routable answer for non-cirrhotic F2-F3 MASH today.

The injectable peptide cohort

Survodutide (Boehringer Ingelheim + Zealand Pharma)

GLP-1 + glucagon dual agonist. Glucagon agonism drives hepatic-fat clearance directly · the mechanistic case for MASH is strong on first principles.

Phase 2 MASH data (2024): 83% achieved at-least-30% relative reduction in liver fat at the high dose. 64.5% achieved MASH resolution without worsening fibrosis at 48 weeks. Striking numbers · drove the FDA Breakthrough Therapy designation for non-cirrhotic MASH with stage 2 or 3 fibrosis.

SYNCHRONIZE-1 phase 3 obesity readout (April 28, 2026): 16.6% mean weight loss at 76 weeks. Below tirzepatide on weight (22.5% at SURMOUNT-1), comparable to Wegovy (15.0%). The obesity-only data does not by itself predict the MASH outcome, but it confirms the dose tolerability + dual-mechanism efficacy at the clinically-relevant exposure.

Phase 3 MASH program in flight: LIVERAGE (non-cirrhotic MASH) + LIVERAGE-Cirrhosis (compensated cirrhotic MASH) + SYNCHRONIZE-MASLD (obesity + MASH overlap) all enrolling. Readouts expected 2026-2027. The cirrhosis arm is unusual in this space · most of the pipeline excludes cirrhotic patients, and a positive readout there opens a label scope nothing else competes for.

Routing posture: HOLD. Phase 3 MASH data is the gate. Once LIVERAGE reads out cleanly + commercial supply settles, the routing decision becomes "for the F2-F3 cohort, is the injectable + glucagon mechanism preferable to oral resmetirom?" That decision needs the head-to-head substudy that does not exist today.

Pemvidutide (Altimmune)

Also GLP-1 + glucagon dual, designed with a higher glucagon-to-GLP-1 receptor ratio than survodutide. The bet: more aggressive on hepatic-fat clearance, less aggressive on appetite suppression. The trade-off shows up in trial endpoints · obesity weight-loss numbers run lower (10-15%), MASH numbers run competitive.

Phase 2b IMPACT-MASH readout (2024): 59.1% MASH resolution without worsening fibrosis at 24 weeks at the high dose. Strong signal for a Phase 2b endpoint window.

Phase 3 status (May 2026): Altimmune received FDA Breakthrough Therapy designation for pemvidutide in MASH on January 5, 2026. The company priced a $75M registered direct offering January 27 + a $225M oversubscribed public offering April 22-27, both targeting Phase 3 MASH program funding. Phase 3 trial start announced for the second half of 2026.

Routing posture: HOLD. Smaller sponsor than Boehringer / Lilly · launch-supply turbulence historically more pronounced for sub-$1B-market-cap launches. Phase 3 readout is years out. The MASH-tilted framing (lower obesity weight-loss, stronger liver) suggests a future routing case for MASH-positive patients with mild-to-moderate (BMI 30-35) obesity where survodutide's higher weight loss is less of a feature.

Retatrutide (Eli Lilly)

GLP-1 + GIP + glucagon triple agonist. The hepatic-fat reduction signals from the early TRIUMPH readouts were striking · the science suggests retatrutide has MASH-relevant activity. But Lilly has not committed a dedicated MASH phase 3 program in the public materials we can verify; the focus stays on obesity (TRIUMPH-1, -2, -4) and cardiovascular outcomes (TRIUMPH-3, the actual CVOT, reads out 2027).

Routing posture: HOLD on MASH specifically. If the obesity + MASH overlap cohort gets a TRIUMPH-style sub-study, the picture changes. Today: not in the MASH routing conversation as a primary indication.

Why we don't route yet

Three reasons, in order of weight:

1. Phase 3 data on the public record is the gate. Phase 2 MASH data (the 2024 IMPACT-MASH 59.1% number, survodutide's 64.5%) is encouraging but predicts phase 3 outcomes imperfectly. Resmetirom's MAESTRO-NASH phase 3 reads in the 25-30% MASH-resolution band · phase 2 of any of these peptides outperforming that on the printed endpoint does not mean the phase 3 will. We have seen too many MASH phase 3 failures (selonsertib, simtuzumab, others) to bet on phase 2 numbers.

2. MASH staging and routing requires biopsy or non-invasive imaging confirmation. Resmetirom's label is non-cirrhotic F2-F3 fibrosis. The injectable peptides will be in a similar stage-restricted lane. Routing readers to a MASH treatment without staged disease confirmation is malpractice-adjacent · and Panya is not a clinic, we route to vendors, the vendor needs the staging confirmation. Today, the path that gets you to a confident MASH staging is a hepatology consult + FibroScan (transient elastography) + possibly a biopsy. The mass-market routing is not yet ready for this.

3. Commercial supply on a MASH peptide approval is years out. Even the most optimistic timeline puts survodutide MASH approval in late 2027 or 2028. The 90-days-of-commercial-supply gate kicks in at that point, not at phase 3 readout. Routing recommendations that assume access two years before approval are routing recommendations to a market that does not exist.

What would change the routing posture

We will start routing on MASH peptides when, in approximate order:

• Phase 3 MASH endpoint matches or beats resmetirom's MAESTRO-NASH 25-30% MASH-resolution band, on a comparable patient population, with safety data clean. LIVERAGE is the first plausible reader.
• FDA approval lands, with an accessible label (covers the MASH cohort that maps to Panya readers, not just diabetes-only or obesity-only co-indication carve-outs).
• First 90 days of commercial supply data show the launch is not pure-cash-only or supply-constrained to the point of being unavailable to non-academic-center patients. Resmetirom's launch has been a useful baseline · slow but real expansion through 2025-2026.
• A clinical lane forms for the staging + routing handshake. Hepatology consult + FibroScan availability + insurance pre-auth process needs to be a realistic expectation before Panya routes anyone toward a MASH-specific treatment.

What we cover today

For readers asking "I have MASH or suspect I have MASH and want options":

• Resmetirom (Rezdiffra) is the routable answer today for non-cirrhotic F2-F3 MASH. The path is: hepatologist + FibroScan or biopsy + Madrigal patient-support program. Insurance handling varies by carrier; prior-auth common. Not a Panya routing recommendation per se because we do not route on MASH yet · but we link out to Madrigal's clinician finder for completeness.
• Tirzepatide / semaglutide for obesity-with-MASH-overlap is a real cohort. The GLP-1s are not MASH treatments, but the metabolic improvements they drive can produce MASH improvement as a downstream effect in a meaningful sub-population. Routing here uses the existing GLP-1 vendor catalog · we do not promote this as MASH treatment. We do flag the overlap when readers ask.

We will revisit this post on each phase 3 readout. The next likely update window: late 2026 to early 2027 for survodutide LIVERAGE.

Companion reading: /blog/peptide-pulse-may-2026 for the broader May 2026 regulatory + readout snapshot. /blog/fda-horizon-six-peptides-2026-2028 for the longer-tail compound coverage including MariTide + retatrutide TRIUMPH-3. /blog/11-signals-vendor-rubric for the methodology behind every routing call.